Next-Generation Liposomal Coenzyme Q 10 : From Formulation to Clinical Evidence via Metazome Technology for Improved Stability and Enhanced Oral Absorption

Abstract

Coenzyme Q 10 (CoQ 10 ) is a mitochondrial cofactor and antioxidant used in cardiovascular, neurodegenerative, and metabolic disorders, but its clinical efficacy is limited by poor solubility, crystallinity, and low oral bioavailability. This study reports a novel liposomal formulation, Metazomal CoQ 10 (MCQ), developed using Metazome technology. CoQ 10 was incorporated into phospholipid bilayers reinforced with gum arabic nanospheres and stabilized by spray drying. Characterization confirmed amorphous dispersion of CoQ 10 within nanosized (~185 nm), spherical, and highly stable vesicles (zeta potential -41.16 mV). MCQ achieved high encapsulation efficiency (88.6 ± 2.3%), favorable loading capacity (14.2 ± 0.8%), and >90% stability after 180 days at room temperature. In a randomized, open-label, crossover study, MCQ showed markedly improved pharmacokinetics compared to conventional CoQ 10 (CCQ), with a 4.3-fold higher AUC 0-t , 3.6-fold higher C max , prolonged T max (16.4 h), extended half-life (20.0 h), and significantly lower elimination rate constant (p < 0.01). These findings establish MCQ, developed using Metazome technology, as a robust and scalable delivery platform that significantly improves stability, absorption, and systemic bioavailability, thereby offering substantial potential for both nutraceutical and therapeutic applications.